GRK2 modulator reduces fat mass while building muscle
Atrogi has revealed positive data from a human trial for its lead candidate ATR-258, a first-in-class small molecule oral GRK2-biased β2-adrenergic modulator.
ATR-258 is designed to target skeletal muscle through a novel GRK2-biased signalling mechanism, with the goal of improving body composition by reducing fat mass while increasing muscle mass and, most importantly, muscle function.
The eight-week study was led by Professor Morten Hostrup, a leading authority on β2-adrenergic receptor pharmacology and physiology in humans, and examined the effects of ATR-258 in 13 overweight or obese subjects.
ATR-258 was well tolerated across three ascending dose levels. Treatment was associated with an approximately 13% improvement in lower-extremity muscle power from baseline, as well as statistically significant mean reductions of 1.1kg in fat mass and increases of 0.8kg in lean mass.
The rise of incretin-based weight-loss medicines has sharpened the focus on preserving muscle, with studies suggesting that 25-45% of weight lost may be lean mass.
Morten Hostrup, Professor and Principal Investigator of the study, commented: “As a researcher who has long studied β2-adrenergic receptor signalling in skeletal muscle, I was curious whether a biased, highly selective GRK2 modulator could harness this pathway differently – driving beneficial changes in muscle mass and function without the trade-offs seen with classical β2-agonists.
“What struck me most was the magnitude of the signal in lower-extremity power. Having worked extensively with classical β2-agonists, I know they can enhance power, but not to the extent we observed here. These findings give us a genuinely intriguing signal about the role of GRK2-biased signalling in muscle physiology, and a strong rationale for taking ATR-258 forward into larger clinical trials.”
